Association between serum BIN1 level and Killip class in patients with acute myocardial infraction

doi:10.12122/j.issn.1673-4254.2024.12.15

Abstract

Abstract:

Objective To investigate the correlation of serum levels of bridging integrating factor 1 (BIN1) with acute myocardial infarction (AMI) and Killip class of the patients. Methods We retrospectively collected the data from 94 patients with AMI and 30 healthy individuals for analysis of the correlations of serum BIN1 levels with Killip class, TIMI scores, and neutrophil-to-lymphocyte ratio (NLR). We also assessed the diagnostic value of BIN1 combined with NLR for AMI. Results Serum BIN1 levels were significantly lower in AMI patients than in the healthy individuals (P=0.032). The AMI patients with Killip class I had significantly lower serum BIN1 levels than the healthy individuals (P=0.008). Serum BIN1 level was an independent predictor of AMI with a predictive value of 0.630 (95% CI: 0.513-0.748) at the optimal cutoff level of 0.341 ng/mL, a specificity of 50%, and a sensitivity of 78.5%. Serum BIN1 level was also an independent predictor for Killip class I group in the AMI patients with a predictive value of 0.672 (95% CI: 0.548-0.797) at the optimal cutoff level of 0.287 ng/mL, a specificity of 74.1%, and a sensitivity of 60%. For AMI diagnosis, the combination of NLR and serum BIN1 level had a predictive value of 0.811 (95% CI: 0.727-0.895) at the optimal cutoff level of 0.548 ng/mL, with a specificity of 92.6% and a sensitivity of 62.2%. There was a positive correlation between serum BIN1 level and TIMI score in AMI patients (r=0.186, P=0.003). Conclusion BIN1 is correlated with AMI and can be helpful for predicting short-term prognosis of the patients, and BIN1 combined with NLR has a high diagnostic value for AMI.

Key words: acute myocardial infraction, bridging integrator 1, Killip classifications, TIMI scores, neutrophils-to-lymphocyte ratio

Yanni WANG, Xia HUANG, Fuheng CHEN, Yuanyuan GAO, Xiangrong CUI, Qin YAN, Xuan JING. Association between serum BIN1 level and Killip class in patients with acute myocardial infraction[J]. Journal of Southern Medical University, 2024, 44(12): 2388-2395.

Figures/Tables 9

References 32

1	North BJ, Sinclair DA. The intersection between aging and cardiovascular disease[J]. Circ Res, 2012, 110(8): 1097-108.
2	Abd El Aziz MT, Abd El Nabi EA, El Hamid MA, et al. Endothelial progenitor cells regenerate infracted myocardium with neovascularisation development[J]. J Adv Res, 2015, 6(2): 133-44.
3	Zhang Y, Jiao L, Sun L, et al. LncRNA ZFAS1 as a SERCA2a Inhibitor to Cause Intracellular Ca(2+) Overload and Contractile Dysfunction in a Mouse Model of Myocardial Infarction[J]. Circ Res, 2018, 122(10): 1354-68.
4	Ridker PM, Rane M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J]. Circ Res, 2021, 128(11): 1728-46.
5	Lin JW, Wang XJ, Zhai SY, et al. Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1[J]. J Hematol Oncol, 2022, 15(1): 128.
6	Sudwarts A, Ramesha S, Gao TW, et al. BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia[J]. Mol Neurodegener, 2022, 17(1): 33.
7	Lionello VM, Kretz C, Edelweiss E, et al. BIN1 modulation in vivo rescues dynamin-related myopathy[J]. Proc Natl Acad Sci USA, 2022, 119(9): e2109576119.
8	Zhou K, Hong TT. Cardiac BIN1 (cBIN1) is a regulator of cardiac contractile function and an emerging biomarker of heart muscle health[J]. Sci China Life Sci, 2017, 60(3): 257-63.
9	Li J, Richmond B, Hong TT. Cardiac T-tubule cBIN1-microdomain, a diagnostic marker and therapeutic target of heart failure[J]. Int J Mol Sci, 2021, 22(5): 2299.
10	Mackrill JJ. Evolution of the cardiac dyad[J]. Philos Trans R Soc Lond B Biol Sci, 2022, 377(1864): 20210329.
11	Díaz-Vesga MC, Flores-Vergara R, Riquelme JA, et al. Polycystin-1 is a crucial regulator of BIN1 expression and T-tubule remodeling associated with the development of dilated cardiomyopathy[J]. Int J Mol Sci, 2022, 24(1): 667.
12	Guo J, Tian QH, Barth M, et al. Human BIN1 isoforms grow, maintain, and regenerate excitation-contraction couplons in adult rat and human stem cell-derived cardiomyocytes[J]. Cardiovasc Res, 2022, 118(6): 1479-91.
13	Hong TT, Cogswell R, James CA, et al. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy[J]. Heart Rhythm, 2012, 9(6): 961-7.
14	Kikuchi M, Tahara Y, Yamaguchi J, et al. Executive summary-acute coronary syndrome in the Japan resuscitation council guidelines for resuscitation 2020[J]. Circ J, 2023, 87(6): 866-78.
15	Zhao LY, Sun YX, Li Y, et al. Chinese expert consensus on blood pressure management after percutaneous coronary intervention. Chin J Hypertens, 2022, 30(6): 506-13.
16	Lavie CJ, Gersh BJ. Acute myocardial infarction: initial manifestations, management, and prognosis[J]. Mayo Clin Proc, 1990, 65(4): 531-48.
17	Djuricic I, Calder PC. Beneficial outcomes of omega-6 and omega-3 polyunsaturated fatty acids on human health: an update for 2021[J]. Nutrients, 2021, 13(7): 2421.
18	Kalayinia S, Arjmand F, Maleki M, et al. MicroRNAs: roles in cardiovascular development and disease[J]. Cardiovasc Pathol, 2021, 50: 107296.
19	Gambardella J, Wang XJ, Ferrara J, et al. Cardiac BIN1 replacement therapy ameliorates inotropy and lusitropy in heart failure by regulating calcium handling[J]. JACC Basic Transl Sci, 2020, 5(6): 579-81.
20	Dibb KM, Louch WE, Trafford AW. Cardiac transverse tubules in physiology and heart failure[J]. Annu Rev Physiol, 2022, 84: 229-55.
21	Nozaki T, Sugiyama S, Sugamura K, et al. Prognostic value of endothelial microparticles in patients with heart failure[J]. Eur J Heart Fail, 2010, 12(11): 1223-8.
22	Shantsila E, Kamphuisen PW, Lip GYH. Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis[J]. J Thromb Haemost, 2010, 8(11): 2358-68.
23	Jiang XX, Zhu YR, Liu HM, et al. Effect of BIN1 on cardiac dysfunction and malignant arrhythmias[J]. Acta Physiol, 2020, 228(3): e13429.
24	Vicent L, Velásquez-Rodríguez J, Valero-Masa MJ, et al. Predictors of high Killip class after ST segment elevation myocardial infarction in the era of primary reperfusion[J]. Int J Cardiol, 2017, 248: 46-50.
25	Milwidsky A, Greidinger D, Frydman S, et al. Echocardiographic killip classification[J]. J Am Soc Echocardiogr, 2022, 35(3): 287-94.
26	Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond[J]. Am J Physiol Endocrinol Metab, 2009, 296(1): E22-E36.
27	Laury-Kleintop LD, Mulgrew JR, Heletz I, et al. Cardiac-specific disruption of Bin1 in mice enables a model of stress- and age-associated dilated cardiomyopathy[J]. J Cell Biochem, 2015, 116(11): 2541-51.
28	Hong TT, Yang HH, Zhang SS, et al. Cardiac BIN1 folds T-tubule membrane, controlling ion flux and limiting arrhythmia[J]. Nat Med, 2014, 20(6): 624-32.
29	Garibaldi M, Böhm J, Fattori F, et al. Novel dominant mutation in BIN1 gene causing mild centronuclear myopathy revealed by myalgias and CK elevation[J]. J Neuromuscul Dis, 2016, 3(1): 111-4.
30	Zhang XW, Xiong H, Duan JL, et al. The prognostic significance of the BIN1 and CCND2 gene in adult patients with acute myeloid leukemia[J]. Indian J Hematol Blood Transfus, 2022, 38(3): 481-91.
31	Ye XM, Zhang P, Zhang YT, et al. GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis[J]. Front Immunol, 2022, 13: 893914.
32	Kala P. Thrombolysis in ST-elevation myocardial infarction is not dead[J]. EuroIntervention, 2021, 16(14): 1129-30.

Variable	Control (n=30)	AMI (n=94)	P
Age (year)	60.32±9.83	61.36±10.44	0.110
Male [n (%)]	13 (43.3)	71 (75.6)	<0.001
ESR (mm/h)	9.47±7.15	10 (12)	0.238
Creatine kinase-MB (ng/mL)	1.2 (0)	1.4 (28.6)	0.665
C-reactive protein (mg/L)	0 (0)	7.5 (18.8)	0.412
Hemoglobin (g/L)	147.19±14.98	143.57±18.76	0.156
Platelet distribution width (fl)	11.4 (1.8)	12.9 (5)	0.010
Neutrophil lymphocyte ratio (%)	1.95±0.72	3.6 (3.4)	<0.001
Glycosylated hemoglobin (%)	5.65±0.38	6.7 (2.7)	0.038
Glucose (mmol/L)	5.1 (0.5)	5.8 (2.8)	0.036
Total cholesterol (mmol/L)	4.83±1.04	4.39±1.08	0.086
Triglyceride (mmol/L)	1.3 (0.9)	1.4 (1.1)	0.214
High-density lipoprotein (mg/dL)	1.31±0.29	1 (0.3)	<0.001
Low-density lipoprotein (mg/dL)	3.02±0.75	2.7 (1)	0.227
Free triiodothyronine (pg/mL)	0 (0)	3.22±0.77	0.092
Thyroid stimulating hormone (uIU/mL)	0 (0)	1.9 (2.2)	0.132
Serum BIN1 (ng/mL)	1 (1.5)	0.7 (0.7)	0.032

Variable	Control (n=30)	AMI (n=94)	P
Age (year)	60.32±9.83	61.36±10.44	0.110
Male [n (%)]	13 (43.3)	71 (75.6)	<0.001
ESR (mm/h)	9.47±7.15	10 (12)	0.238
Creatine kinase-MB (ng/mL)	1.2 (0)	1.4 (28.6)	0.665
C-reactive protein (mg/L)	0 (0)	7.5 (18.8)	0.412
Hemoglobin (g/L)	147.19±14.98	143.57±18.76	0.156
Platelet distribution width (fl)	11.4 (1.8)	12.9 (5)	0.010
Neutrophil lymphocyte ratio (%)	1.95±0.72	3.6 (3.4)	<0.001
Glycosylated hemoglobin (%)	5.65±0.38	6.7 (2.7)	0.038
Glucose (mmol/L)	5.1 (0.5)	5.8 (2.8)	0.036
Total cholesterol (mmol/L)	4.83±1.04	4.39±1.08	0.086
Triglyceride (mmol/L)	1.3 (0.9)	1.4 (1.1)	0.214
High-density lipoprotein (mg/dL)	1.31±0.29	1 (0.3)	<0.001
Low-density lipoprotein (mg/dL)	3.02±0.75	2.7 (1)	0.227
Free triiodothyronine (pg/mL)	0 (0)	3.22±0.77	0.092
Thyroid stimulating hormone (uIU/mL)	0 (0)	1.9 (2.2)	0.132
Serum BIN1 (ng/mL)	1 (1.5)	0.7 (0.7)	0.032

Variable	Univariate analysis		Multivariate analysis
Variable	OR (95% CI)	P	OR (95% CI)	P
Age (year)	5.429 (2.904-10.151)	0.263	-	-
Male [n (%)]	0.248 (0.105-0.586)	0.002	0.337 (0.122-0.932)	0.036
ESR (mm/h)	3.556 (0.359-35.197)	0.278	-	-
CK-MB (ng/mL)	3.909 (1.574-9.703)	0.102	-	-
CRP (mg/L)	6.947 (2.355-10.489)	<0.001	-	0.106
HB (g/L)	1.504 (1.224-1.848)	<0.001	0.51 (0.157-1.660)	0.264
PDW (fl)	1.598 (1.318-1.937)	<0.001	4.88 (1.506-15.812)	0.008
NLR (%)	1.731 (1.403-2.136)	<0.001	3.119 (1.162-8.368)	0.024
HbA1c (%)	2.532 (1.716-3.738)	<0.001	8.628(1.899-39.198)	0.005
Glucose (mmol/L)	1.681 (1.381-2.048)	<0.001	-	0.269
TC (mmol/L)	1.604 (1.311-1.962)	<0.001	0.302 (0.101-0.908)	0.033
Triglyceride (mmol/L)	1.632 (1.365-1.950)	<0.001	1.311 (0.523-3.285)	0.564
HDL (mg/dL)	1.694 (1.354-2.119)	<0.001	0.347 (0.021-5.857)	0.463
LDL (mg/dL)	1.641 (1.337-2.041)	<0.001	0.536 (0.206-1.392)	0.200
FT3 (pg/mL)	4.916 (2.152-11.230)	<0.001	0.254 (0.015-4.267)	0.341
TSH (uIU/mL)	4.753 (2.072-10.904)	<0.001	2.401 (0.271-21.301)	0.432
Serum BIN1 (ng/mL)	1.825 (1.418-2.350)	<0.001	0.389 (0.161-0.942)	0.031

Variable	Univariate analysis		Multivariate analysis
Variable	OR (95% CI)	P	OR (95% CI)	P
Age (year)	5.429 (2.904-10.151)	0.263	-	-
Male [n (%)]	0.248 (0.105-0.586)	0.002	0.337 (0.122-0.932)	0.036
ESR (mm/h)	3.556 (0.359-35.197)	0.278	-	-
CK-MB (ng/mL)	3.909 (1.574-9.703)	0.102	-	-
CRP (mg/L)	6.947 (2.355-10.489)	<0.001	-	0.106
HB (g/L)	1.504 (1.224-1.848)	<0.001	0.51 (0.157-1.660)	0.264
PDW (fl)	1.598 (1.318-1.937)	<0.001	4.88 (1.506-15.812)	0.008
NLR (%)	1.731 (1.403-2.136)	<0.001	3.119 (1.162-8.368)	0.024
HbA1c (%)	2.532 (1.716-3.738)	<0.001	8.628(1.899-39.198)	0.005
Glucose (mmol/L)	1.681 (1.381-2.048)	<0.001	-	0.269
TC (mmol/L)	1.604 (1.311-1.962)	<0.001	0.302 (0.101-0.908)	0.033
Triglyceride (mmol/L)	1.632 (1.365-1.950)	<0.001	1.311 (0.523-3.285)	0.564
HDL (mg/dL)	1.694 (1.354-2.119)	<0.001	0.347 (0.021-5.857)	0.463
LDL (mg/dL)	1.641 (1.337-2.041)	<0.001	0.536 (0.206-1.392)	0.200
FT3 (pg/mL)	4.916 (2.152-11.230)	<0.001	0.254 (0.015-4.267)	0.341
TSH (uIU/mL)	4.753 (2.072-10.904)	<0.001	2.401 (0.271-21.301)	0.432
Serum BIN1 (ng/mL)	1.825 (1.418-2.350)	<0.001	0.389 (0.161-0.942)	0.031

Variable Control (n=30)		Killip Ⅰ (n=58)	Killip Ⅱ (n=13)	Killip Ⅲ (n=5)	Killip Ⅳ (n=12)	P
Age (year)	43.63±9.83	60.21±10.42	61.15±9.90	61.00±11.47	70.33±6.71	0.001*
Male [n (%)]	16.3 (13)	56.3 (45)	11.3 (9)	5 (4)	11.3 (9)	0.022*
ESR (mm/h)	9.47±7.15	10.10±5.03	26.00±19.52	4 (0)	17.17±12.84	0.169
BNP (pg/mL)	-	75.7 (139.1)	68.4 (158.7)	437.57±558.40	792.82±649.66	0.012*
cTnI (ng/mL)	-	4111.9 (25542.3)	13379.2 (22279.2)	13125.2 (0)	1483 (19718.4)	0.559
FT3 (pmol/L)	0 (0)	3.28±0.79	3.46±0.29	3.00±0.67	2.8 (1.3)	0.141
TSH (mol/L)	0 (0)	2.09±1.45	2.82±1.39	0.6 (0)	1.81±1.41	0.192
D-Dimer (ng/mL)		101 (194.5)	230.75±181.98	148.80±113.60	169.5 (428.7)	0.892
CKMB (ng/mL)	10.2 (0)	2.5 (29.5)	1.1 (47)	1 (0)	10.7 (0)	0.971
hs-CRP (mg/L)	0 (0)	2.6 (3.8)	10.3 (6.7)	2.42±2.10	9.55±1.42	0.040*
TnI (ng/mL)	-	1.1 (4.9)	1 (8)	0.1 (5877.1)	15.97±15.60	0.388
CRP (mg/L)	0 (0)	12.4 (16.3)	79.86±87.14	20.5 (0)	2.8 (12)	0.503
HB (g/L)	147.19±14.98	142.95±18.00	136.15±24.10	146.3±12.8	140.64±12.96	0.582
PDW (fl)	11.4 (1.8)	12.4 (4.6)	13.57±3.89	14.6±3.04	15.9 (5.9)	0.017*
NLR (%)	2.8 (2.9)	3 (2.6)	3.98 (3.53)	5.32±2.55	7.97±4.10	0.001*
HbA1c (%)	5.65±0.38	6.7 (2.2)	7.33±1.57	6.43±1.23	6.2 (2.5)	0.247
Glucose (mmol/L)	5.1 (0.5)	5.4 (2.5)	7 (7.04)	4.8 (2.9)	5.9 (3.6)	0.024*
TC (mmol/L)	4.83±1.04	4.29±1.10	4.52±1.19	4.48±1.44	4.3 (1.5)	0.403
Triglyceride (mmol/L)	1.3 (0.9)	1.4(1)	1.60±0.64	2.34±2.06	1.60±0.84	0.757
HDL (mg/dL)	1.31±0.29	1 (0.4)	1.1 (0.6)	1.41±0.61	1.1 (0.8)	0.019*
LDL (mg/dL)	3.02±0.75	2.74±0.87	2.7 (1.6)	3.1 (1.1)	2.7 (1)	0.658
CK (ng/mL)	76 (0)	327.60 (1712.2)	3437.18±3034.36	1574.00±2290.10	94.5 (1288.83)	0.192
Serum BIN1 (ng/mL)	1 (1.5)	0.63 (0.5)^a	0.68 (0.55)	2.2 (6)^b	1.5 (12.1)^c	0.008*